RU2408735C2 - Способ предсказания ответа на лечение - Google Patents

Способ предсказания ответа на лечение Download PDF

Info

Publication number
RU2408735C2
RU2408735C2 RU2008108907/10A RU2008108907A RU2408735C2 RU 2408735 C2 RU2408735 C2 RU 2408735C2 RU 2008108907/10 A RU2008108907/10 A RU 2008108907/10A RU 2008108907 A RU2008108907 A RU 2008108907A RU 2408735 C2 RU2408735 C2 RU 2408735C2
Authority
RU
Russia
Prior art keywords
marker
growth factor
marker protein
protein
transforming growth
Prior art date
Application number
RU2008108907/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2008108907A (ru
Inventor
Йоахим МЁКК (DE)
Йоахим МЁКК
Андреас ШТРАУСС (DE)
Андреас Штраусс
Герхард ЦУГМАЙЕР (DE)
Герхард ЦУГМАЙЕР
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2408735(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2008108907A publication Critical patent/RU2008108907A/ru
Application granted granted Critical
Publication of RU2408735C2 publication Critical patent/RU2408735C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
RU2008108907/10A 2005-08-12 2006-05-24 Способ предсказания ответа на лечение RU2408735C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12
EP05017663.5 2005-08-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2010115252/10A Division RU2010115252A (ru) 2005-08-12 2010-04-19 Способ предсказания ответа на лечение

Publications (2)

Publication Number Publication Date
RU2008108907A RU2008108907A (ru) 2009-09-20
RU2408735C2 true RU2408735C2 (ru) 2011-01-10

Family

ID=35511140

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2008108907/10A RU2408735C2 (ru) 2005-08-12 2006-05-24 Способ предсказания ответа на лечение
RU2010115252/10A RU2010115252A (ru) 2005-08-12 2010-04-19 Способ предсказания ответа на лечение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2010115252/10A RU2010115252A (ru) 2005-08-12 2010-04-19 Способ предсказания ответа на лечение

Country Status (32)

Country Link
US (2) US7700299B2 (cg-RX-API-DMAC10.html)
EP (2) EP2196547B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009504142A (cg-RX-API-DMAC10.html)
KR (2) KR20110074921A (cg-RX-API-DMAC10.html)
CN (2) CN101705287A (cg-RX-API-DMAC10.html)
AR (1) AR057323A1 (cg-RX-API-DMAC10.html)
AT (2) ATE539171T1 (cg-RX-API-DMAC10.html)
AU (2) AU2006281746B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0615001A2 (cg-RX-API-DMAC10.html)
CA (1) CA2616913A1 (cg-RX-API-DMAC10.html)
CL (1) CL2010000720A1 (cg-RX-API-DMAC10.html)
CR (1) CR9686A (cg-RX-API-DMAC10.html)
CY (1) CY1111612T1 (cg-RX-API-DMAC10.html)
DE (1) DE602006019265D1 (cg-RX-API-DMAC10.html)
DK (1) DK1915460T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP088171A (cg-RX-API-DMAC10.html)
ES (1) ES2356066T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20110171T1 (cg-RX-API-DMAC10.html)
IL (1) IL188923A0 (cg-RX-API-DMAC10.html)
MA (1) MA31549B1 (cg-RX-API-DMAC10.html)
MX (1) MX2008001926A (cg-RX-API-DMAC10.html)
NO (1) NO20080371L (cg-RX-API-DMAC10.html)
NZ (1) NZ565270A (cg-RX-API-DMAC10.html)
PL (1) PL1915460T3 (cg-RX-API-DMAC10.html)
PT (1) PT1915460E (cg-RX-API-DMAC10.html)
RS (1) RS51859B (cg-RX-API-DMAC10.html)
RU (2) RU2408735C2 (cg-RX-API-DMAC10.html)
SI (1) SI1915460T1 (cg-RX-API-DMAC10.html)
TW (1) TW200741010A (cg-RX-API-DMAC10.html)
UA (1) UA93989C2 (cg-RX-API-DMAC10.html)
WO (1) WO2007019899A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201102688B (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
UA90480C2 (uk) * 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) * 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
NZ586544A (en) * 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US9879267B2 (en) * 2008-03-14 2018-01-30 Genentech, Inc. Genetic variations associated with drug resistance
NZ589143A (en) * 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011132182A1 (en) * 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
WO2012094636A2 (en) * 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
EP2764364B1 (en) * 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
CN104349773A (zh) 2012-01-06 2015-02-11 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
CA2919477A1 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP2876442A1 (en) 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
JP2017528430A (ja) 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
EP3534948A1 (en) 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MY199134A (en) 2018-05-25 2023-10-17 Bioneer Corp Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
EP4568994A1 (en) * 2022-08-09 2025-06-18 Heligenics, Inc. Method for evaluating clinical relevance of genetic variance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005118627A (ru) * 2005-06-15 2006-12-20 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделени Российской академии медицинских наук ГУ НИИонкологии ТНЦ СО РАМН (RU) Способ иммуногитохимического анализа рецепторов стероидных гормонов

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
WO2004053497A2 (en) * 2002-12-11 2004-06-24 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
WO2005049829A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
WO2005047534A2 (en) 2003-10-28 2005-05-26 Bayer Healthcare Ag Methods and compositions for the response prediction of malig-nant neoplasia to treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005118627A (ru) * 2005-06-15 2006-12-20 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделени Российской академии медицинских наук ГУ НИИонкологии ТНЦ СО РАМН (RU) Способ иммуногитохимического анализа рецепторов стероидных гормонов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLEMS A et al: "Antibody therapy for breast cancer" Anticancer Res, 2005 May-Jun, реферат. *

Also Published As

Publication number Publication date
EP2196547B1 (en) 2011-12-28
AU2011202339A1 (en) 2011-06-09
MX2008001926A (es) 2008-03-24
RU2010115252A (ru) 2011-10-27
EP1915460A2 (en) 2008-04-30
KR20110074921A (ko) 2011-07-04
CR9686A (es) 2008-02-20
TW200741010A (en) 2007-11-01
AR057323A1 (es) 2007-11-28
WO2007019899A3 (en) 2007-04-05
AU2006281746B2 (en) 2011-06-23
DK1915460T3 (da) 2011-01-31
ATE493514T1 (de) 2011-01-15
PT1915460E (pt) 2011-03-17
NZ565270A (en) 2011-05-27
RS51859B (sr) 2012-02-29
CY1111612T1 (el) 2015-10-07
SI1915460T1 (sl) 2011-04-29
MA31549B1 (fr) 2010-08-02
US7700299B2 (en) 2010-04-20
EP2196547A1 (en) 2010-06-16
UA93989C2 (ru) 2011-03-25
CN101705287A (zh) 2010-05-12
WO2007019899A8 (en) 2010-08-05
WO2007019899A2 (en) 2007-02-22
IL188923A0 (en) 2008-08-07
RU2008108907A (ru) 2009-09-20
KR20080034922A (ko) 2008-04-22
BRPI0615001A2 (pt) 2011-04-26
CN101405405A (zh) 2009-04-08
CA2616913A1 (en) 2007-02-22
US20100112603A1 (en) 2010-05-06
ES2356066T3 (es) 2011-04-04
EP1915460B1 (en) 2010-12-29
ECSP088171A (es) 2008-03-26
CL2010000720A1 (es) 2010-12-03
NO20080371L (no) 2008-05-09
ZA201102688B (en) 2012-01-25
US20070037228A1 (en) 2007-02-15
AU2006281746A1 (en) 2007-02-22
ATE539171T1 (de) 2012-01-15
DE602006019265D1 (de) 2011-02-10
JP2009504142A (ja) 2009-02-05
HRP20110171T1 (hr) 2011-04-30
PL1915460T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
HRP20110171T1 (hr) Postupak za predviđanje reakcije na liječenje inhibitorom her dimerizacije
JP2009504142A5 (cg-RX-API-DMAC10.html)
CN105229164B (zh) 指示癌症疗法的srm测定
RU2011150279A (ru) Фосфодиэстераза 4d7 как маркер рака предстательной железы
JP6612414B2 (ja) Ｐｄ−ｌ１に対するｓｒｍアッセイ
WO2010002911A2 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
AU2011241174B2 (en) Method and kit for cancer diagnosis
KR102067327B1 (ko) 최적의 암 치료를 위한 Her2 단백질 정량
JP6441215B2 (ja) 肺組織像を細分類するためのｓｒｍ／ｍｒｍ分析
JP2020144104A (ja) 腫瘍組織の分子プロファイリングのためのｓｒｍ／ｍｒｍアッセイ
JP2020522501A (ja) Ｔ−ｄｍ１による癌治療成績の予測方法
WO2012097276A2 (en) Bcl-2-like protein 11 srm/mrm assay
RU2011150291A (ru) Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы
Going et al. Ras p21 in breast tissue: associations with pathology and cellular localisation
Alba et al. HER2 status determination using RNA-ISH—a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer
CN106255765B (zh) 针对酪氨酸蛋白激酶受体ufo(axl)蛋白质的srm/mrm测定
Becker et al. Extraction of phosphorylated proteins from formalin-fixed cancer cells and tissues
CN106255766B (zh) 针对雄激素受体(ar)蛋白质的srm/mrm测定
JP2020514734A (ja) 腫瘍組織の免疫プロファイリング
CN103217534A (zh) 肺癌标志物sbp-1及其用途
Igci et al. Septin 7 immunoexpression in papillary thyroid carcinoma: a preliminary study
KR20200050374A (ko) 노치 경로 단백질용 srm/mrm 분석
CN107850605B (zh) 间皮素(msln)蛋白质的srm/mrm测定
KR20190095523A (ko) 세린/트레오닌-단백질 키나제 수용체 B-raf(BRAF)에 대한 SRM/MRM 검정
KR102147928B1 (ko) 공기오염물질 노출 여부 확인용 바이오마커 및 이를 이용한 공기오염물질 노출 확인 방법

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120525